Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Mount Sinai

Neither a doctor nor a teaching hospital

Research payments

$582,346

78 payments

Through program year 2025, Mount Sinai is reported as receiving $582,346 in research payments, across 78 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $267,937 20
2024 Research $118,641 24
2023 Research $60,500 11
2022 Research $1,001 5
2020 Research $310 1
2019 Research $133,957 17

Breakdown

Who paid Research payments · program years 2019–2025
  1. Alnylam Pharmaceuticals Inc. $278,130 43 payments
  2. Kyowa Kirin, Inc. $140,659 1 payment
  3. Recor Medical Inc $115,000 1 payment
  4. Boston Scientific Corporation $20,698 19 payments
  5. Stryker Corporation $18,460 4 payments
  6. Davol Inc. $8,010 1 payment
  7. Rhythm Pharmaceuticals, Inc. $1,312 8 payments
  8. Amgen Inc. $77 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Phase II study of mogamulizumab with EPOCH in patients with aggressive T cell lymphoma $140,659 1 payment
  2. ULTRA-HFIB Redo - ISR $115,000 1 payment
  3. APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) $113,580 8 payments
  4. The Study of an Investigational Drug, Patisiran ALN-TTR02, for the Treatment of Transthyretin TTR-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 Patisiran $51,617 6 payments
  5. ILLUMINATE-A A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 $44,633 5 payments
  6. APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) $42,036 1 payment
  7. HELIOS-A A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis hATTR Amyloidosis $19,170 1 payment
  8. Elegance $12,043 5 payments
  9. A Post-Market Clinical Evaluation of the Treatment of Tibia Fractures With the T2 Alpha Tibia Nailing System $9,230 2 payments
  10. A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail Greater Trochanter GT of the T2 Alpha Femur Antegrade GTPF Nailing System $9,230 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record